v" An experimental model of subarachnoid hemorrhage (SAH) in the Sprague-Dawley rat induces angiographically demonstrable, reproducible biphasic vasospasm of the vertebrobasilar system. The acute vasospasm is maximum at 10 minutes and the maximum late vasospasm occurs 2 days after the SAH. Brattleboro rats, which are deficient in arginine vasopressin (AVP), do not have acute vasospasm after SAH but exhibit a degree of late vasospasm that is not significantly different from that seen in Sprague-Dawley rats. Cisternal injection of AVP induced acute vasospasm in Sprague-Dawley rats with a duration similar to that seen after cisternal blood injection; however, at 2 days, the vessel diameter was normal. Intravenous AVP antagonist or intracisternal AVP antiserum administered prior to the SAH prevented the development of acute vasospasm without affecting the late phase. The data suggest that an increased release of AVP in the cerebrospinal fluid is involved in the development of acute cerebral vasospasm.
C EREBRAL vasospasm is a major complication of subarachnoid hemorrhage (SAH) following rupture of an aneurysm. 1.9,16,30,40 The lack of knowledge about the mechanism causing vasospasm has been a stumbling-block in the development of therapy for this condition. The diversity in the treatments suggested for vasospasm reflects this lack of understanding of its cause and stresses the importance of further investigation.
In a model of SAH in the Sprague-Dawley rat, we have demonstrated biphasic, angiographically visible vasospasm with maximum acute vasospasm l0 minutes after the SAH and maximum late vasospasm 2 days later. 6 Lesioning of the ascending catecholamine pathways from the A, and A2 nuclei (nomenclature according to Dahlstr6m and Fuxe 4) in the medulla oblongata prior to SAH has been found to prevent the development of both acute and late spasm in this rat model. 37 Selective lesions placed in the A2 nucleus prevent development of both phases of vasospasm, whereas lesions made in the A~ nucleus only prevent the development of late vasospasm, suggesting that acute and late vasospasm have different mechanisms. 36 The A~ and A2 nuclei project to the paraventricular and the supraoptic nuclei, n influencing arginine vasopressin (AVP) secretion, 3,5,z5' 32 and also extend to the median eminence. 27,z8 The median eminence is a conduit where hypothalamic peptides are released into the blood or cerebrospinal fluid (CSF) or are transmitted to the pituitary. 26 Lesioning the median eminence prevents the development of both phases of vasospasm. 38 The present communication reports the results of an investigation of the role played by AVP in the development of vasospasm after SAH. Brattleboro rats, which congenitally lack the capacity to produce AVP, were used for this study. In addition, the effect of an AVP antagonist and AVP antiserum on vasospasm development was investigated.
Materials and Methods
The experiments were performed on male Brattleboro and Sprague-Dawley rats, each weighing between 200 and 320 gm. The data for the Sprague-Dawley rats, which were subjected to SAH and followed by angiography, were taken from earlier studies. 6,37 catheter, 0.9 mm in outside diameter and 0.5 mm in inside diameter, was permanently implanted with one end connected to the cisterna magna and the other end sutured subcutaneously to the musculature on the vertex, as described elsewhere. 6 Stage H. Three to 7 days after insertion of the cisternal catheter, the animals were prepared for bilateral vertebral angiography. Anesthesia was initiated with 4% halothane. The animals were intubated orally with a premature infant feeding tube* and artificially ventilated with a 70% nitrous oxide and 30% oxygen mixture. Catheters were inserted into a femoral artery and vein for continuous blood pressure monitoring and for infusion of drugs, respectively. Radiopaque polyethylene catheters,t 0.9 mm in outside diameter and 0.5 mm in inside diameter, were inserted into the axillary arteries for angiography. The end of the catheter was tapered and the tip was placed about 2 mm distal to the origin of the vertebral arteries. 6 During insertion of the catheters, 0.75% halothane was added to the gas mixture. Heparin, 75 IU/kg, was given intravenously. After surgery, delivery of halothane was terminated and suxamethonium chloride (Celocurin) was given: 3 mg/ kg to the Sprague-Dawley rats and 1 mg/kg to the Brattleboro rats. Half an hour was allowed to pass before angiography was performed. Blood samples were drawn periodically for measurement of pH, PaO2, and PaCO2.
For angiography, an x-ray tube with a 0.2 x 0.2-mm focus spot:~ was used with the following exposure data: 80 mA, 60 kV, 0.16 seconds, and x 2.86 magnification. The angiograms were made using Kodak NMB mammographic film. Metrizamide (Amipaque) in a concentration of 370 mg I/ml was simultaneously injected into both axillary catheters over 2 to 3 seconds. The vertebral and basilar artery diameters were measured with a technique similar to that described by Gabrielsen and Greitz. 12 Under a magnifying glass, the contour of the vessels on the angiograms was enhanced with a sharp soft pencil. The diameter of the vessel was then measured with the aid of a precision-calibrated measuring lens of fixed magnification and lens film distance. A vascular index representing the mean value of the diameters at four preselected points within the vertebrobasilar system was calculated. 6 Each animal served as its own control. Following a control angiogram, about 0.03 ml of CSF was aspirated and 0.07 or 0.3 ml of homologous blood was injected via the cisternal catheter. During injection of blood, the animal's head was lowered by tilting its body 20 ~ . Ten minutes after the SAH, angiography was repeated. In a previous communication, this was found to be the time at which maximum acute spasm took place. 6 After angiography, * Premature infant feeding tube, No. 8-CR, manufactured by Bard International, Ltd., Clacton, England.
t Polyethylene catheters manufactured by Surgimed A/S, Olstykke, Denmark.
~X-ray tube, Opti-100/12/15 HSG, manufactured by Elema-Siemens, Erlangen, West Germany. the catheters were removed and axillary arteries were ligated distal to the superficial radial artery to prevent occlusion of the vessel and to facilitate perfusion of the limb. The animals were extubated when fully awake.
Stage III. Two days after the SAH, the time at which maximum late spasm was found in previous studies, 6 the animals were reanesthetized and intubated. After reinsertion of the axillary and femoral catheters, angiography was repeated. Following the examination, the animals were sacrificed.
Delivery of A VP, A VP Antagonist, A VP Antiserum, or Serum
Arginine vasopressin (10 pg in 0.07 ml saline) was delivered into the subarachnoid space via the cisternal catheter. Control rats received 0.07 ml saline. The AVP antagonist, BL-D-VI (3 ug/kg in 0.3 ml saline), was injected intravenously. The AVP antiserum, which was produced in rabbits according to the method of Sofroniew, et al., 33 was injected in a volume of 0. l0 ml into the subarachnoid space via the cisternal catheter. The control animal for the latter group received normal rabbit serum (0.10 ml) intracisternally.
Experimental Groups
The animals were separated into five experimental groups. Group I included two subgroups of six SpragueDawley rats that received either 0.07 or 0.3 ml of homologous blood intracisternally. All of these animals underwent angiography 10 minutes and 2 days after the SAH. Group II comprised 12 Brattleboro rats that were subjected to SAH. Two of these animals underwent angiography at both l0 minutes and after 2 days, and 10 were examined angiographically at either 10 minutes or 2 days post-SAH. Group III included 16 Sprague-Dawley rats that received AVP intracisternally and underwent angiography 5, 10, 30, and 90 minutes and 2 days after the injection. Control animals were given a saline injection in the same amount. Group IV was composed of six Sprague-Dawley rats, each given AVP antagonist intravenously 15 minutes before cisterhal injection of 0.3 ml blood. These animals had angiography at 10 minutes and 2 days post-SAH. Group V included six Sprague-Dawley rats that received AVP antiserum intrathecally in the subarachnoid space 15 minutes before cisternal injection of 0.3 ml blood. The animals were subjected to angiography 10 minutes and 2 days post-SAH. The control rats received normal rabbit serum injections.
Statistical Analysis
The data were evaluated statistically by means of Student's t-test analysis.
Results

Physiological Parameters
The physiological parameters in the different experimental groups are summarized in Tables 1 to 3 During the 5 minutes following intracisternal injection of AVP in the Sprague-Dawley rats, there was a significant increase in MABP of about 15% (p < 0.5) which gradually decreased to normal (Table 2 ). In the animals receiving AVP antagonist or AVP antiserum, there was a gradual, nonsignificant decrease in MABP of about 10%, which returned to normal over 10 minutes.
Spasmogenic Effect of SAH
Cisternal injection of 0.07 ml blood in the Brattleboro rats did not cause any vasoconstriction in the vertebrobasilar system at 10 minutes after the injection, but vasospasm of about 17% was observed at 2 days post-SAH (Figs. 1 and 2 ). In the Sprague-Dawley animals receiving 0.07 ml blood, vasoconstriction of 34% and 23% was noted at 10 minutes and 2 days post-SAH, respectively. There was no significant difference in the degree of vasospasm between the Brattleboro and the Sprague-Dawley rats at 2 days post-SAH. The pre-SAH mean vessel diameters in the vertebrobasilar system were similar in the two groups.
Spasmogenic Effect of Vasopressin
Cisternal injection of 10 pg AVP in 0.07 ml saline caused a 39% and 25% vasoconstriction in the vertebrobasilar system at 5 and 10 minutes after the injection, respectively. The constriction lasted for at least 90 minutes (Fig. 3) ; by 2 days post-SAH the vessel diameter had returned to normal. Intracisternal injection of saline did not cause any significant change in the diameters of the vertebrobasilar system.
Effect on Vasospasm of A VP Antagonist or A VP Antiserum
There was no acute vasospasm in the Sprague-Dawley rats receiving AVP antagonist intravenously or AVP antiserum intracisternally 15 minutes prior to SAH. At 2 days post-SAH, there was no significant change in the degree of vasospasm as compared to control values FlG. 2. Vertebrobasilar angiograms in a Brattleboro rat before subarachnoid hemorrhage (SAH) (A) and 10 minutes post-SAH (B), and in a Sprague-Dawley rat before SAH (C) and 10 minutes post-SAH (D). Vasospasm is not seen 10 minutes after the SAH in the Brattleboro rat, while there is severe vasospasm at 10 minutes in the Sprague-Dawley rat. (Fig. 4) . The Sprague-Dawley rats receiving 0.3 ml blood had a vasoconstriction of 36% at 10 minutes and 23% at 2 days post-SAH. Intracisternal injection of normal rabbit serum prior to the SAH caused acute or late vasospasm that was about 10% less than that seen in animals receiving blood only (p < 0.05).
Morbidity and Mortafity
The Sprague-Dawley rats subjected to SAH were drowsy during the 2 days post-SAH, but no paralysis was noted in any of the animals and no animals died. Despite the absence of acute vasospasm, a large proportion of the Brattleboro rats died within the first 24 hours after SAH. There was no mortality in the animals receiving AVP or AVP antiserum. Two of six animals receiving AVP antagonist died during the first 24 hours after SAH.
Discussion
The present study demonstates that an SAH in the Brattleboro rat, which lacks the capacity to produce vasopressin, does not induce acute vasospasm, although the degree of late vasospasm is the same as that seen in the Sprague-Dawley rat. It was further shown that intracisternal injection of AVP produced acute vasospasm with a time course similar to that seen in normal rats after an SAH. Intravenous injection of the AVP antagonist prior to an SAH prevented the development of acute vasospasm without significantly affecting the degree of late vasospasm. Cisternal injection of AVP antiserum before SAH had a similar effect.
An argument could be made that the absence of vasospasm in the Brattleboro rats reflects a difference in strain. Therefore, we evaluated the effect of SAH in Long-Evans rats, which are the same strain as Brattle-
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boro rats but are not deficient in AVP. The Long-Evans rats developed acute spasm of a degree similar to that seen in Sprague-Dawley rats (TJ Delgado, et al., unpublished data).
In our basic SAH model we injected eilher 0.07 or 0.3 ml blood intracisternally. 6 The Brattleboro rats included in the present study received 0.07 ml since the injection of 0.3 ml blood was associated with an extremely high mortality rate. Decreasing the amount of blood only minimally reduced the degree of vasospasm. 6 D6czi, et al., 7 used Brattleboro rats in an SAH model to evaluate the role of vasopressin in brain fluid and electrolyte balance after SAH. Their results suggested that vasopressin is involved in brain edema formation after SAH. The effect on the cerebral vessels was not evaluated.
Vasopressin in plasma and CSF has been measured after SAH in both clinical and experimental studies. Jenkins, et aL, '5 examined the AVP concentration in the plasma and CSF of 11 SAH patients. Two of these patients had an increased AVP level in CSF 3 or 4 weeks after their SAH. Mather, et aL, 22 found an increase in plasma and/or CSF levels of vasopressin in about one-fourth of their SAH patients. The time of sampling in relation to the SAH was not indicated. Rap and Chwalbifiska-Moneta z9 injected blood into the subarachnoid space of cats, and found an acute increase in plasma AVP (the pre-SAH measurement ranged from 5 to 10 #U/ml, while the immediate post-SAH measurement ranged from 7.6 to 720 uU/ml). The CSF values were not measured.
In a previous communication, 36 we have demonstrated that the catecholamine-containing neurons in the Az nucleus of the medulla oblongata are involved in the development of acute spasm. The A2 nucleus projects to the paraventricular and supraoptic nuclei 3z ..>~.--..,,'--.,.
--.
"./~,. arterial infusion of small (1 to 12 uU/min) doses of vasopressin in unanesthetized goats, while Ko~niewska, et al., is.19 demonstrated a temporary CBF increase with administration of a large intra-arterial bolus of vasopressin (140 uU and 2 to 10 mU) in anesthetized cats and rats, respectively.
Our data suggest that AVP is involved in the development of acute vasospasm. Cisternal injection of a physiological dose of AVP (10 pg is three times the amount of AVP normally present in the CSF in rats weighing 300 gm) s gives rise to vasospasm that reaches a maximum shortly after the injection and has a duration similar to that seen in the acute stage after blood injection. The acute vasospasm is maximum at 10 minutes after cisternal injection of blood. The relative delay in the appearance of spasm after SAH as compared to cisternal AVP injection is consistent with a certain delay in the liberation and spread of AVP in the subarachnoid space. The prevention of acute vasospasm by an AVP antagonist injected intravenously or AVP antiserum given intracisternally, also supports the role of the peptide in acute spasm. The AVP antagonist crosses the blood-brain barrier and competitively blocks the vascular AVP receptor. The antiserum given intravenously did not prevent acute vasospasm (TJ Delgado, et al., unpublished data), probably because the antibody does not cross the blood-brain barrier. This suggests that it is the AVP level in CSF that is of importance for vasospasm and not the level in plasma. The effect of cisternal injection of antiserum further supports this suggestion. Measurement of AVP levels in CSF immediately after a bleed would be of interest; however, this has not been feasible in rats with a SAH.
The AVP antagonist and AVP antiserum had no effect on the degree of late vasospasm when administered similarly on Day 2, 15 minutes prior to repeated angiography (TJ Delgado, et al., unpublished data).
Raised CSF levels of AVP have been found in neurological disorders associated with increased intracranial pressure, such as brain tumors, hemorrhage, and hydrocephalus. 34 It is generally accepted that these patients do not have vasospasm. The reason for the lack of vasospasm in these patients is not known, but it might represent a regulation phenomenon 13,35 (in which receptor sensitivity decreases with prolonged exposure to an agonist), which is often seen with hormones including AVP. The latter might explain the absence of acute vasospasm in SAH patients undergoing rebleeding during angiography. 41 The data in this study suggest that an increased release of AVP in CSF is involved in the development of acute cerebral vasospasm.
